Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Actinogen Medical (3AC) Stock Price & Analysis

0 Followers

3AC Stock Chart & Stats

€0.02-€0.00(-4.76%)
At close: 5:30 PM GMT+1
€0.02€0.03€0.04Aug 4Aug 19Sep 3Sep 14Sep 28Oct 15
Day’s Range
EUR 0.02 - EUR 0.02
52-Week Range
EUR 0.02 - EUR 0.05
Previous Close
EUR 0.02
Volume
N/A
Average Volume (3M)
11.77K
Market Cap
EUR 95.76M
Enterprise Value
EUR 90.43M
Total Cash (Recent Filing)
EUR 16.73M
Total Debt (Recent Filing)
EUR 4.78M
Price to Earnings (P/E)
―
Beta
0.07
Next Earnings
Feb 24, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Positive Equity Cushion

Positive equity and growth in the asset base provide Actinogen with a financial cushion while it advances its clinical programs. This does not remove funding needs, but it offers greater balance-sheet resilience than a company operating with negative net assets.

Moderate Leverage

Debt remains moderate relative to equity, limiting the immediate burden of financial leverage on a development-stage business. This supports flexibility in allocating capital to research and trials, although the upward trend means leverage should continue to be monitored.

Focused Drug Pipeline

Actinogen has a focused therapeutic strategy built around Xanamem, an oral small-molecule candidate addressing neurological and neuropsychiatric disorders. If clinical development succeeds, this platform could support meaningful product differentiation and a durable commercial opportunity.

Bears Say

Revenue Collapse

The fall to zero revenue indicates that Actinogen currently lacks dependable top-line generation, increasing reliance on funding while clinical programs progress. Without a recovery in revenue or successful commercialization, the company has limited internal capacity to finance ongoing development.

Deep Operating Losses

Large operating and net losses show that the current business model is not yet profitable and remains financially dependent on successful drug development. Continued losses can reduce equity over time and constrain the company’s ability to invest without raising additional capital.

Persistent Cash Burn

Persistent negative operating and free cash flow mean Actinogen is not self-funding its activities. The substantial FY2026 outflow raises the importance of securing external capital and increases the risk that future financing could dilute existing shareholders or slow development.

Actinogen Medical News

3AC FAQ

What was Actinogen Medical ’s price range in the past 12 months?
Actinogen Medical lowest stock price was €0.02 and its highest was €0.05 in the past 12 months.
What is Actinogen Medical ’s market cap?
Actinogen Medical ’s market cap is €95.76M.
When is Actinogen Medical ’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Actinogen Medical ’s earnings last quarter?
Actinogen Medical released its earnings results on Aug 27, 2026. The company reported -€0.001 earnings per share for the quarter.
Is Actinogen Medical overvalued?
According to Wall Street analysts Actinogen Medical ’s price is currently Undervalued.
Does Actinogen Medical pay dividends?
Actinogen Medical does not currently pay dividends.
What is Actinogen Medical ’s EPS estimate?
Actinogen Medical ’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Actinogen Medical have?
Actinogen Medical has 3,874,168,200 shares outstanding.
What happened to Actinogen Medical ’s price movement after its last earnings report?
Actinogen Medical reported an EPS of -€0.001 in its last earnings report. Following the earnings report the stock price went up 27.273%.
Which hedge fund is a major shareholder of Actinogen Medical ?
Currently, no hedge funds are holding shares in DE:3AC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology